In contrast, through the integration of readily available parameters at the district hospital level - both clinical (family history of HCC or cirrhosis and clinical diagnosis of decompensated cirrhosis) and laboratory (ALT, AST, and platelet counts) - we were able to accurately identify 79% of individuals eligible for treatment and 87% of those ineligible for treatment. The gene discussed is GPT; the disease is Cirrhosis.